HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil A, Spitzmüller A, Brieu N, Haneder S, Shumilov A, Meier A, Cecchi F, Barkell A, Harder N, Mittermaier K, Hidalgo-Sastre A, Alleze R, Schick M, Schmidt G, Sade H, Tsuchihashi Z, Suto F, Gustavson M, Barrett JC, Carroll D.
Kapil A, et al.
Sci Rep. 2024 May 27;14(1):12129. doi: 10.1038/s41598-024-61957-9.
Sci Rep. 2024.
PMID: 38802399
Free PMC article.
Clinical Trial.